The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008.
Reasons to Purchase
- Quantify the performance of each of leading 20 cancer therapies in the seven major markets over the period 2008 to 2018
- Assess the changing key opportunities and threats both for currently marketed and pipeline cancer therapy brands
- Identify the leading brands in this market over the next 10 years and understand the key factors driving their success